ASCO GU 2019 renal highlights
ASCO GU 2019 renal highlights
ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC
Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma
Whole genome and transcriptome analysis of metastatic adrenocortical carcinoma
Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer
Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer
CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC
Changes to the CME system in France
The importance of CME publishing
Can balanced CME truly be achieved without independence?
What is 'global collaboration' and why is it important?
Using the Outcomes Framework to improve patient care